190 related articles for article (PubMed ID: 34416705)
1. Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor.
Dome JS; Mullen EA; Dix DB; Gratias EJ; Ehrlich PF; Daw NC; Geller JI; Chintagumpala M; Khanna G; Kalapurakal JA; Renfro LA; Perlman EJ; Grundy PE; Fernandez CV
J Natl Compr Canc Netw; 2021 Aug; 19(8):978-985. PubMed ID: 34416705
[TBL] [Abstract][Full Text] [Related]
2. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
Dix DB; Fernandez CV; Chi YY; Mullen EA; Geller JI; Gratias EJ; Khanna G; Kalapurakal JA; Perlman EJ; Seibel NL; Ehrlich PF; Malogolowkin M; Anderson J; Gastier-Foster J; Shamberger RC; Kim Y; Grundy PE; Dome JS;
J Clin Oncol; 2019 Oct; 37(30):2769-2777. PubMed ID: 31449468
[TBL] [Abstract][Full Text] [Related]
4. New approaches to risk stratification for Wilms tumor.
Nelson MV; van den Heuvel-Eibrink MM; Graf N; Dome JS
Curr Opin Pediatr; 2021 Feb; 33(1):40-48. PubMed ID: 33394739
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
Evageliou N; Renfro LA; Geller J; Perlman E; Kalapurakal J; Paulino A; Dix D; Eklund MJ; Murphy AJ; Romao RLP; Ehrlich PF; Varela CR; Vallance K; Fernandez CV; Dome JS; Mullen EA
Cancer; 2024 Mar; 130(5):792-802. PubMed ID: 37902955
[TBL] [Abstract][Full Text] [Related]
6. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.
Dome JS; Graf N; Geller JI; Fernandez CV; Mullen EA; Spreafico F; Van den Heuvel-Eibrink M; Pritchard-Jones K
J Clin Oncol; 2015 Sep; 33(27):2999-3007. PubMed ID: 26304882
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.
Dix DB; Seibel NL; Chi YY; Khanna G; Gratias E; Anderson JR; Mullen EA; Geller JI; Kalapurakal JA; Paulino AC; Perlman EJ; Ehrlich PF; Malogolowkin M; Gastier-Foster JM; Wagner E; Grundy PE; Fernandez CV; Dome JS
J Clin Oncol; 2018 Jun; 36(16):1564-1570. PubMed ID: 29659330
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification for wilms tumor: current approach and future directions.
Dome JS; Perlman EJ; Graf N
Am Soc Clin Oncol Educ Book; 2014; ():215-23. PubMed ID: 24857079
[TBL] [Abstract][Full Text] [Related]
9. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
Fawzy M; Bahanassy A; Samir A; Hafez H
Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
[TBL] [Abstract][Full Text] [Related]
10. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
Park JE; Noh OK; Lee Y; Choi HS; Han JW; Hahn SM; Lyu CJ; Lee JW; Yoo KH; Koo HH; Jeong SY; Sung KW
Cancer Res Treat; 2020 Apr; 52(2):438-445. PubMed ID: 31505910
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
12. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
[TBL] [Abstract][Full Text] [Related]
13. Hepatic metastasis at diagnosis in patients with Wilms tumor is not an independent adverse prognostic factor for stage IV Wilms tumor: a report from the Children's Oncology Group/National Wilms Tumor Study Group.
Ehrlich PF; Ferrer FA; Ritchey ML; Anderson JR; Green DM; Grundy PE; Dome JS; Kalapurakal JA; Perlman EJ; Shamberger RC
Ann Surg; 2009 Oct; 250(4):642-8. PubMed ID: 19730241
[TBL] [Abstract][Full Text] [Related]
14. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
[TBL] [Abstract][Full Text] [Related]
15. Pediatric genitourinary tumors.
Castellino SM; McLean TW
Curr Opin Oncol; 2007 May; 19(3):248-53. PubMed ID: 17414644
[TBL] [Abstract][Full Text] [Related]
16. Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.
Daw NC; Chi YY; Kim Y; Mullen EA; Kalapurakal JA; Tian J; Khanna G; Geller JI; Perlman EJ; Ehrlich PF; Warwick AB; Grundy PE; Fernandez CV; Dome JS;
Eur J Cancer; 2019 Sep; 118():58-66. PubMed ID: 31325873
[TBL] [Abstract][Full Text] [Related]
17. The evolution of treatment for Wilms tumor.
Green DM
J Pediatr Surg; 2013 Jan; 48(1):14-9. PubMed ID: 23331787
[TBL] [Abstract][Full Text] [Related]
18. Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children's Oncology Group Study, AREN03B2.
Lovvorn HN; Renfro LA; Benedetti DJ; Kotagal M; Phelps HM; Ehrlich PF; Lo AC; Sandberg JK; Treece AL; Gow KW; Glick RD; Davidoff AM; Cost NG; Dix DB; Fernandez CV; Dome JS; Geller JI; Mullen EA
J Am Coll Surg; 2024 Apr; 238(4):733-749. PubMed ID: 38251681
[TBL] [Abstract][Full Text] [Related]
19. Wilms tumor.
Pater L; Melchior P; Rübe C; Cooper BT; McAleer MF; Kalapurakal JA; Paulino AC
Pediatr Blood Cancer; 2021 May; 68 Suppl 2():e28257. PubMed ID: 32893998
[TBL] [Abstract][Full Text] [Related]
20. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group.
Ehrlich P; Chi YY; Chintagumpala MM; Hoffer FA; Perlman EJ; Kalapurakal JA; Warwick A; Shamberger RC; Khanna G; Hamilton TE; Gow KW; Paulino AC; Gratias EJ; Mullen EA; Geller JI; Grundy PE; Fernandez CV; Ritchey ML; Dome JS
Ann Surg; 2017 Sep; 266(3):470-478. PubMed ID: 28795993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
